No Data
No Data
Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
In the overall trial population, survival results numerically favored Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan but did not reach statistical significanceTROPION-Lung01 previously met th
RevolKa Signed Master Service Agreement With Daiichi Sankyo
RevolKa will create highly functional proteins by using AI-driven platform RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President
AstraZeneca and Daiichi Sankyo's ADC Improves Survival in NSCLC Trial
Jefferies Adjusts Daiichi Sankyo's Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy
Daiichi Sankyo (TYO:4568) has an average rating of buy and price targets ranging from 4,200 yen to 6,800 yen, according to analysts polled by Capital IQ.
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
ENHERTU late-breaking data from DESTINY-Breast06 continues to redefine the classification and treatment of metastatic breast cancer with new data in patients with HER2 low and HER2 ultralow disease
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court
IHH Healthcare's (SGX:Q0F, KLSE:IHH) indirect wholly owned subsidiary Northern TK Venture submitted a brief to a court in Japan over the company's position in respect of damages sought from Japan's Da
No Data